Related Experiment Video

Updated: Jun 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Hiroshi Sakamoto1, Toshiyuki Tsukaguchi, Sayuri Hiroshima

  • 1Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan. sakamotohrs@chugai-pharm.co.jp

Cancer Cell
|May 18, 2011
PubMed

Insights

A new drug, CH5424802, effectively targets anaplastic lymphoma kinase (ALK) in cancers like nonsmall cell lung cancer. This potent inhibitor shows promise for treating ALK-driven tumors, even those with resistance mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) is a tyrosine kinase implicated in various cancers due to genetic alterations.
  • Constitutive ALK activation, through translocations, amplifications, or mutations, drives tumor growth in specific malignancies.

Purpose of the Study:

  • To identify and characterize CH5424802, a novel, orally available inhibitor targeting ALK.
  • To evaluate the antitumor efficacy of CH5424802 against ALK-driven cancers, including those with known resistance mechanisms.

Main Methods:

  • In vitro and in vivo studies were conducted using cancer cell lines and models harboring ALK gene alterations.
  • The study assessed the inhibitory activity of CH5424802 against wild-type ALK and the ALK L1196M gatekeeper mutation.

Main Results:

  • CH5424802 demonstrated potent and selective inhibition of ALK.
  • The compound exhibited preferential antitumor activity in nonsmall cell lung cancer (NSCLC) and anaplastic large-cell lymphoma (ALCL) models with EML4-ALK and NPM-ALK fusions, respectively.
  • CH5424802 effectively inhibited the ALK L1196M mutation, overcoming a common resistance mechanism and blocking associated cell growth.

Conclusions:

  • CH5424802 is a promising ALK inhibitor with a unique scaffold and favorable pharmacokinetic properties.
  • The drug shows significant potential for treating patients with ALK-driven tumors, including those resistant to other kinase inhibitors.
  • Clinical evaluation of CH5424802 is warranted for ALK-altered malignancies.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...